DiscGenics, Inc., a pioneering biotechnology firm headquartered in the United States, focuses on developing innovative regenerative therapies for spinal disc degeneration. Founded in 2013, the company has made significant strides in the field of orthobiologics, particularly with its flagship product, IDCT, a cell-based therapy designed to restore disc health and alleviate pain. With a strong presence in the US and expanding operations in key international markets, DiscGenics is positioned at the forefront of the regenerative medicine industry. The company’s unique approach combines advanced cellular technology with a commitment to improving patient outcomes, setting it apart from traditional treatment options. Notable achievements include successful clinical trials that underscore the efficacy of its therapies, solidifying DiscGenics' reputation as a leader in spinal health innovation.
How does DiscGenics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
DiscGenics, Inc.'s score of 23 is lower than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
DiscGenics, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that DiscGenics may not have established formal commitments to carbon reduction or sustainability initiatives at this time. As the industry increasingly prioritises climate action, it will be essential for DiscGenics to consider developing and communicating its climate commitments to align with broader environmental goals.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
DiscGenics, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

